Shares of Asterias Biotherapeutics Inc (NYSE:AST) have received an average broker rating score of 1.25 (Strong Buy) from the four brokers that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a buy rating and three have given a strong buy rating to the company.

Brokerages have set a 12-month consensus target price of $8.88 for the company and are expecting that the company will post ($0.15) EPS for the current quarter, according to Zacks. Zacks has also assigned Asterias Biotherapeutics an industry rank of 103 out of 265 based on the ratings given to related companies.

A number of brokerages have weighed in on AST. HC Wainwright set a $12.00 price target on shares of Asterias Biotherapeutics and gave the company a “buy” rating in a research report on Wednesday, August 16th. Zacks Investment Research cut shares of Asterias Biotherapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th.

A number of hedge funds have recently bought and sold shares of the stock. Teachers Advisors LLC lifted its holdings in Asterias Biotherapeutics by 13.1% in the 2nd quarter. Teachers Advisors LLC now owns 58,028 shares of the biotechnology company’s stock valued at $206,000 after acquiring an additional 6,714 shares during the last quarter. State Street Corp lifted its stake in Asterias Biotherapeutics by 24.1% during the second quarter. State Street Corp now owns 328,717 shares of the biotechnology company’s stock valued at $1,169,000 after buying an additional 63,773 shares in the last quarter. California State Teachers Retirement System lifted its stake in Asterias Biotherapeutics by 4.6% during the second quarter. California State Teachers Retirement System now owns 47,764 shares of the biotechnology company’s stock valued at $170,000 after buying an additional 2,100 shares in the last quarter. Finally, Family Management Corp lifted its stake in Asterias Biotherapeutics by 15.6% during the second quarter. Family Management Corp now owns 47,424 shares of the biotechnology company’s stock valued at $168,000 after buying an additional 6,416 shares in the last quarter.

Asterias Biotherapeutics (NYSE AST) opened at 3.25 on Wednesday. The firm’s market capitalization is $162.43 million. Asterias Biotherapeutics has a 12-month low of $2.83 and a 12-month high of $5.80. The firm has a 50-day moving average of $3.35 and a 200 day moving average of $3.35.

Asterias Biotherapeutics (NYSE:AST) last released its earnings results on Monday, August 14th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.18). Asterias Biotherapeutics had a negative net margin of 2,762.03% and a negative return on equity of 86.25%. The firm had revenue of $0.32 million during the quarter, compared to the consensus estimate of $1.25 million. On average, equities analysts predict that Asterias Biotherapeutics will post ($0.62) EPS for the current year.

TRADEMARK VIOLATION WARNING: This news story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/13/zacks-asterias-biotherapeutics-inc-ast-receives-consensus-recommendation-of-strong-buy-from-brokerages.html.

Asterias Biotherapeutics Company Profile

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

Get a free copy of the Zacks research report on Asterias Biotherapeutics (AST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related stocks with our FREE daily email newsletter.